Zai Lab Ltd (ZLAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zai Lab Ltd (ZLAB) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Zai Lab reported EPS of -$0.41, above the -$0.59 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ZLAB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
ZLAB Earnings Call
The latest ZLAB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, ZLAB beat 19, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $108.21M, down 6.8% from $116.09M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.41 | -$0.59 | -$0.67 - -$0.50 | +30.51% | Beat | N/A | 6 | 2 up, 3 down | Nov 5, 2026 | $108.21M |
| Jun 30, 2026 | -$0.46 | -$0.66 | -$0.99 - -$0.58 | +30.30% | Beat | N/A | 6 | 0 up, 4 down | Aug 6, 2026 | $106.31M |
| Mar 31, 2026 | -$0.46 | -$0.29 | N/A | -58.13% | Miss | N/A | 5 | 0 up, 3 down | May 7, 2026 | $99.61M |
| Dec 31, 2025 | -$0.46 | -$0.44 | -$0.75 - -$0.22 | -4.55% | Miss | N/A | 6 | 1 up, 2 down | Feb 26, 2026 | $127.60M |
| Sep 30, 2025 | -$0.33 | -$0.29 | -$0.37 - -$0.21 | -13.79% | Miss | N/A | 6 | 0 up, 2 down | Nov 6, 2025 | $116.09M |
| Jun 30, 2025 | -$0.37 | -$0.37 | -$0.56 - -$0.35 | 0.00% | In line | N/A | 6 | 1 up, 1 down | Aug 7, 2025 | $109.98M |
| Mar 31, 2025 | -$0.45 | -$0.55 | -$0.69 - -$0.47 | +18.18% | Beat | N/A | 5 | N/A | May 8, 2025 | $106.49M |
| Dec 31, 2024 | -$0.80 | -$0.63 | -$0.72 - -$0.48 | -26.32% | Miss | N/A | 5 | 2 up, 0 down | Feb 27, 2025 | $109.07M |
| Sep 30, 2024 | -$0.42 | -$0.78 | -$0.90 - -$0.68 | +46.15% | Beat | N/A | 6 | 1 up, 0 down | Nov 12, 2024 | $102.27M |
| Jun 30, 2024 | -$0.82 | -$0.73 | -$0.85 - -$0.59 | -12.33% | Miss | N/A | 6 | 0 up, 0 down | Aug 6, 2024 | $100.50M |
| Mar 31, 2024 | -$0.50 | -$0.92 | -$1.09 - -$0.75 | +45.65% | Beat | N/A | 6 | 1 up, 0 down | May 8, 2024 | $87.15M |
| Dec 31, 2023 | -$0.98 | -$0.87 | -$0.97 - -$0.78 | -12.64% | Miss | N/A | 6 | 0 up, 0 down | Feb 27, 2024 | $65.83M |
| Sep 30, 2023 | -$0.71 | -$1.03 | -$1.25 - -$0.71 | +31.07% | Beat | N/A | 6 | 0 up, 2 down | Nov 7, 2023 | $69.23M |
| Jun 30, 2023 | -$1.25 | -$0.81 | -$1.04 - -$0.66 | -54.32% | Miss | N/A | 5 | 0 up, 0 down | Aug 7, 2023 | $68.86M |
| Mar 31, 2023 | -$0.51 | -$0.97 | -$1.05 - -$0.86 | +47.42% | Beat | N/A | 5 | 1 up, 0 down | May 9, 2023 | $62.80M |
| Dec 31, 2022 | -$0.65 | -$1.11 | -$1.33 - -$1.01 | +41.44% | Beat | N/A | 5 | 0 up, 0 down | Feb 28, 2023 | $62.60M |
| Sep 30, 2022 | -$1.68 | -$1.25 | -$1.68 - -$0.20 | -34.40% | Miss | N/A | 5 | 0 up, 0 down | Nov 9, 2022 | $57.54M |
| Jun 30, 2022 | -$1.44 | -$1.07 | -$1.44 - -$0.93 | -34.58% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2022 | $48.18M |
| Mar 31, 2022 | -$0.86 | -$1.23 | N/A | +30.08% | Beat | N/A | 4 | 0 up, 0 down | May 10, 2022 | $46.72M |
| Dec 31, 2021 | -$2.17 | -$1.33 | N/A | -63.16% | Miss | N/A | N/A | N/A | Mar 1, 2022 | $44.17M |
| Sep 30, 2021 | -$1.01 | -$1.27 | -$1.74 - -$1.01 | +20.47% | Beat | N/A | 5 | 0 up, 0 down | Nov 9, 2021 | $43.10M |
| Jun 30, 2021 | -$1.76 | -$1.39 | -$1.76 - -$1.33 | -26.62% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2021 | $36.94M |
| Mar 31, 2021 | -$2.64 | -$2.30 | -$2.30 - -$0.86 | -14.78% | Miss | N/A | 2 | N/A | May 10, 2021 | $20.10M |
| Dec 31, 2020 | -$0.40 | -$0.99 | N/A | +59.78% | Beat | N/A | N/A | N/A | Mar 1, 2021 | $15.09M |
| Sep 30, 2020 | -$0.40 | -$0.40 | N/A | +0.45% | Beat | N/A | N/A | N/A | Dec 2, 2020 | $14.65M |
| Jun 30, 2020 | -$0.67 | -$0.99 | N/A | +32.32% | Beat | N/A | N/A | N/A | Aug 13, 2020 | $10.99M |
| Mar 31, 2020 | -$0.99 | -$0.99 | N/A | +0.01% | Beat | N/A | N/A | N/A | Jun 3, 2020 | $8.22M |
| Dec 31, 2019 | -$0.68 | -$0.60 | N/A | -13.33% | Miss | N/A | 1 | N/A | Jan 21, 2020 | $4.65M |
| Sep 30, 2019 | -$0.60 | -$0.60 | N/A | +0.78% | Beat | N/A | N/A | N/A | Nov 27, 2019 | $4.92M |
| Jun 30, 2019 | -$0.43 | -$0.67 | N/A | +35.82% | Beat | N/A | N/A | N/A | Sep 3, 2019 | $1.71M |
| Mar 31, 2019 | -$0.67 | -$0.44 | N/A | -52.66% | Miss | N/A | N/A | N/A | May 29, 2019 | $1.71M |
| Dec 31, 2018 | -$0.68 | -$0.45 | N/A | -51.11% | Miss | N/A | N/A | N/A | Mar 7, 2019 | $129452 |
| Sep 30, 2018 | -$0.33 | -$0.40 | N/A | +17.50% | Beat | N/A | N/A | N/A | Nov 28, 2018 | $64726 |
| Jun 30, 2018 | -$0.26 | -$0.38 | N/A | +31.58% | Beat | N/A | N/A | N/A | Aug 30, 2018 | N/A |
| Mar 31, 2018 | -$0.25 | -$0.17 | N/A | -47.06% | Miss | N/A | N/A | N/A | May 2, 2018 | N/A |
| Dec 31, 2017 | -$3.95 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | N/A |
| Sep 30, 2017 | -$0.21 | -$0.23 | N/A | +8.70% | Beat | N/A | N/A | N/A | Nov 15, 2017 | N/A |
| Jun 30, 2017 | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 21, 2017 | N/A |
| Mar 31, 2017 | -$11.49 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | N/A |
| Dec 31, 2016 | -$0.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.61, after -$2.54 the year before. It was -$1.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.61 | N/A |
| Dec 31, 2024 | -$2.54 | N/A |
| Dec 31, 2023 | -$3.45 | N/A |
| Dec 31, 2022 | -$4.63 | N/A |
| Dec 31, 2021 | -$7.58 | N/A |
| Dec 31, 2020 | -$2.46 | N/A |
| Dec 31, 2019 | -$2.38 | N/A |
| Dec 31, 2018 | -$2.48 | N/A |
| Dec 31, 2017 | -$23.20 | N/A |
| Dec 31, 2016 | -$1.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,995 | 12 | |
| 2026Q2 | Jun 30, 2026 | 4,456 | 12 | |
| 2026Q1 | Mar 31, 2026 | 3,695 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,955 | 13 | |
| 2025Q3 | Sep 30, 2025 | 6,375 | 13 | |
| 2025Q2 | Jun 30, 2025 | 6,887 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,237 | 16 | |
| 2024Q4 | Dec 31, 2024 | 7,360 | 13 |
2026Q3 Earnings Call
Opening remarks
Christine Chiou Senior Vice President of Investor Relations Thank you, operator. Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO, and Chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yizhe Wang, our Operating Partner, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on November 5, 2026, for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.
Samantha Du Founder, CEO, and Chairperson Thanks, Christine. Good morning and good evening, everyone. We're entering one of the most important periods in Zai Lab's history. I founded Zai Lab to discover and develop innovative medicines for patients around the world. We have spent years building the talent, scientific capabilities, and infrastructure to make that possible. With zoci advancing toward a potential U.S. BLA submission next year, that vision is within our reach. Our first-line ESMO data strengthened our confidence that zoci can become the ADC backbone in small cell lung cancer. We are advancing the zoci-IO doublet into a global phase III study and building on it through our T-cell engager collaborations with Amgen and BI. The next two years are pivotal. By year-end, we expect three registrational studies underway across small cell lung cancer and neuroendocrine carcinomas. In 2027, we anticipate two registrational results and our first potential U.S. BLA submission, positioning us for a U.S. launch as early as 2028. This would be a defining achievement for our company. Our recent $250 million financing further strengthens our ability to deliver on the plan. Our ambition extends well beyond zoci. Next week, we will present the first clinical data for ZL-1503, our internally developed bispecific for atopic dermatitis. We also expect three additional oncology and immunology assets in clinical development next year. Meanwhile, we continued to strengthen our China commercial business. Net product revenue grew 2% sequentially, and our China business remained profitable. This performance is consistent with the stabilization we outlined on our second quarter call.
Frequently Asked Questions About ZLAB
Did ZLAB beat earnings estimates last quarter?
Yes. Zai Lab reported EPS of -$0.41 for the quarter ended Sep 30, 2026, above the -$0.59 estimate, a 30.51% surprise.
What EPS do analysts expect from ZLAB next quarter?
The consensus EPS estimate for Zai Lab for the quarter ending Dec 31, 2026 is -$0.06 from 4 analysts, with estimates from -$0.06 to -$0.06.
How often does ZLAB beat earnings estimates?
Zai Lab beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -2.97%.
ZLAB pages: Overview, Earnings, Forecast, Financials, Competitors